Research Excellence Award
Ketan Ruparelia — De Montfort University, United Kingdom
Ketan Ruparelia is a researcher affiliated with De Montfort University in Leicester, United Kingdom. His documented research works include studies spanning pharmaceutical and cancer-related research, including drug-delivery systems, anticancer compounds, phytochemical analysis, and medicinal chemistry. The available research record provides evidence of publications involving chemotherapy-related nanocarriers, synthetic resveratrol analogues, plant secondary metabolism, and flavone-based enzyme inhibition. These works provide a scholarly basis for considering his profile within pharmaceutical research and cancer-focused scientific activity. [1]
Abstract
Ketan Ruparelia’s documented research profile is associated with pharmaceutical and biomedical research, with particular relevance to cancer research, drug delivery, phytochemical investigation, and anticancer compound development. The available ORCID record lists five research works and identifies De Montfort University as his employment affiliation. [1]
Keywords
Ketan Ruparelia, pharmaceutical research, cancer research, drug delivery, nanomedicine, siRNA delivery, multidrug-resistant cancer, chemotherapy, mesoporous silica nanoparticles, anticancer compounds, resveratrol analogues, medicinal chemistry, phytochemical analysis, plant secondary metabolism, flavones, tyrosinase inhibitors, pharmaceutical biotechnology, International Top Pharmaceutical Awards.
Introduction
Pharmaceutical research increasingly combines medicinal chemistry, drug-delivery engineering, molecular biology, and natural-product investigation to address complex therapeutic challenges. Ruparelia’s documented works intersect several of these areas, particularly through research involving anticancer compounds and pharmaceutical delivery technologies. [1][3]
Research Profile
The ORCID record identifies Ketan Ruparelia and associates the profile with De Montfort University in Leicester, Leicestershire, United Kingdom. The employment entry specifies the position of Senior Technician in Health & Life Sciences, while the record also lists five works with Crossref-linked publication information. The supplied bibliometric profile reports 39 documents, 1,939 citations, and an h-index of 20, with Cancer Research identified as the principal subject area. [1]
Research Contributions
A central contribution documented in the available record concerns pharmaceutical nanotechnology and targeted nucleic-acid delivery. The 2025 European Journal of Pharmaceutics and Biopharmaceutics article examines electrosprayed core-shell polyethyleneimine and phospholipid-coated mesoporous silica nanoparticles for co-delivery of KAZ3 and MDR-1 siRNA. [1]
Publications
Ketan Ruparelia’s publications span pharmaceutical nanotechnology, cancer research, medicinal chemistry, and phytochemical analysis. His 2025 article on electrosprayed core-shell nanoparticles investigated KAZ3 and MDR-1 siRNA co-delivery for chemotherapy in multidrug-resistant colon cancer. [1] His other works examine synthetic resveratrol analogues, indanone-based chalcone analogues, plant secondary metabolism, and flavone tyrosinase inhibition. [2]
Research Impact
The reported bibliometric profile indicates 39 documents, 1,939 citations, and an h-index of 20. These figures provide quantitative indicators of scholarly visibility within the supplied profile, while the underlying publication record demonstrates activity across pharmaceutical delivery, cancer research, medicinal chemistry, and phytochemical investigation. In particular, nanoparticle-mediated siRNA delivery connects pharmaceutical formulation with cancer biology, whereas resveratrol analogue research links synthetic chemistry with anticancer investigation. [1][3]
Award Suitability
The documented research profile is relevant to a Research Excellence Award within a pharmaceutical research context because it encompasses multiple areas directly connected with drug development and cancer-oriented pharmaceutical science. The evidence includes peer-reviewed journal articles, DOI-indexed works, and research involving drug-delivery systems and anticancer compounds. [1][3]
Conclusion
Ketan Ruparelia’s documented research profile reflects interdisciplinary activity relevant to pharmaceutical and cancer research. His recorded works encompass nanocarrier-based siRNA delivery, anticancer resveratrol analogues, synthetic chemistry, phytochemical analysis, and enzyme-inhibitor research. The combination of these research areas provides a substantive scholarly basis for recognition under a pharmaceutical research excellence category.[1][3]
External Links
References
- Sayed, E., Ruparelia, K., Zafar, S., Faheem, A., Fatouros, D., Arshad, M. S., Singh, N., & Ahmad, Z. (2025). Novel electrosprayed core-shell polyethyleneimine and phospholipid coated MSNs for Co-delivery of KAZ3 and MDR-1 siRNA for efficient chemotherapy in multidrug-resistant colon cancer. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2025.114838
- Pal, P., Ruparelia, K. C., Arroo, R. R. J., & Brucoli, F. C. (2025). A Green Chemistry Approach for the Synthesis of Indanones as Fixed Ring Chalcone Analogues. Preprints. https://www.preprints.org/manuscript/202504.1089
- Ruparelia, K. C., Zeka, K., Beresford, K. J. M., Wilsher, N. E., Potter, G. A., Androutsopoulos, V. P., Brucoli, F., & Arroo, R. R. J. (2024). CYP1-Activation and Anticancer Properties of Synthetic Methoxylated Resveratrol Analogues. Molecules, 29(2). https://doi.org/10.3390/molecules29020423
- Arroo, R. R. J., Bhambra, A. S., Hano, C., Renda, G., Ruparelia, K. C., & Wang, M. F. (2021). Analysis of plant secondary metabolism using stable isotope-labelled precursors. Phytochemical Analysis. https://doi.org/10.1002/pca.2955
- Arroo, R. R. J., Sari, S., Barut, B., Özel, A., Ruparelia, K. C., & Şöhretoğlu, D. (2020). Flavones as tyrosinase inhibitors: kinetic studies in vitro and in silico. Phytochemical Analysis. https://doi.org/10.1002/pca.2897